Altimmune (ALT) Stock Price, Quote, News & History | Benzinga

SPY777.75−0.04%QQQ743.07−0.40%BTC/USD83,133.30+1.71%DIA516.15−0.34%GLD381.13−0.27%TLT78.36+0.40%

Altimmune Inc (ALT) Stock Price, Quote, News & History

ALTNASDAQ

Trade with Public

Trade with Public

$2.43

-0.13-5.08%

Last update: Oct 13, 4:02 PM

$2.50

-0.06-2.34%

OverviewNews Earnings Forecast Events Price Targets Financials Sentiment Ownership Compare Options Stock Report

Key Statistics

Open

$2.56

Close

$2.43

Volume / Avg.

3.70M / 4.16M

Day Range

$2.50 - $2.50

52 Wk Range

2.55 - 6.44

Market Cap

$497.97M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

24

Short Interest

23.72%

Days to Cover

10.54

Recent Altimmune Inc News

Altimmune Says Lead Drug Shows Significant Alcohol Reduction in Mid-Stage Study

Altimmune reports positive Phase 2 RECLAIM trial data for pemvidutide in AUD and plans to request an EOP2 meeting with the FDA.

Vandana Singh

Why Is Altimmune Stock Falling Today?

Altimmune shares fall after a $225 million offering raises dilution concerns while funding key late-stage trials.

Nabaparna Bhattacharya

ASGN Posts Downbeat Q1 Results, Joins Medpace, ServiceNow And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

Dow futures fall 200 pts, ASGN stock drops 25.2% after missing earnings estimates. Other stocks declining in pre-market trading. Photo: Shutterstock

Avi Kapoor

ASGN Posts Downbeat Q1 Results, Joins Medpace, ServiceNow And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

Dow futures fall 200 pts, ASGN stock drops 25.2% after missing earnings estimates. Other stocks declining in pre-market trading. Photo: Shutterstock

Avi Kapoor

Altimmune (ALT) Shares Slide On $75 Million Stock Offering

Altimmune shares are tumbling on Wednesday following the company's announcement of a $75 million registered direct offering of common stock.

Henry Khederian

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-76.51M

Investing Cash Flow (TTM)

-453.61M

Financing Cash Flow (TTM)

410.02M

Free Cash Flow (TTM)

-76.56M

Capital Expenditure (TTM)

-54.00K

Net Change in Cash (TTM)

-120.10M

Analyst Trends and Forecast

1

May

1

Jun

1

Sep

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.3

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$217.43M

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

10458.60

PB Ratio (TTM)

1.05

Earnings Yield % (TTM)

-29.63%

Earnings Yield % (FWD)

-24.56%

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

$2.44

Company Debt

Total Debt

$34.74M

LT Debt

$34.74M

LT Debt Issuance (TTM)

$20.40M

LT Debt Repayment (TTM)

-

Total Cash

$63.01M

Debt to Equity

0.08

Issuance of Debt (TTM)

$20.40M

Repayment of Debt (TTM)

-